David Venables

David Venables – CEO


Dr David Venables is currently CEO of Synpromics Ltd, a synthetic biology company developing promoters to enable controlled gene expression in support of gene and cell therapy applications and has recently completed two successful fund raising rounds of £2.25M in total. He has previously has served as VP – CMC for NightstaRx, an ophthalmology focused gene therapy company. Having performed the CMC due diligence on behalf of Syncona Partners leading up to the investment by Syncona he then established the development and manufacturing strategy and partnerships required to take through to licensure; CEO of Anatara Therapeutics (a life sciences company he managed through private fund raising and IPO in Australia); CEO of Ark Therapeutics with responsibility for leading the company through a transition to a viral contract development and manufacturing service model and ultimately a sale of the business assets, and Managing Director of BioMelior Services Ltd, providing management and consultancy services to the biopharmaceutical industry and investment funds in the areas of bioprocess CMC, CMO/CRO services and business & product development strategy within the vaccine, gene therapy and cell therapy sectors. Previously at Intercell, he was responsible for building Intercell’s manufacturing capabilities in Europe and the USA. As Site Head for vaccine manufacturing operations in the UK he was responsible for the European and US licensure, pre-approval inspection and commercial supply of Ixiaro®, a Japanese Encephalitis vaccine, followed as Chief Operating Officer of Intercell USA Inc. based in Maryland, USA.

He was awarded his PhD in Mammalian Cell Fermentation from Surrey University, after which he joined Medeva PLC as Group Leader – Process Development, involved in the successful European licensure of a recombinant Hepatitis B vaccine.  In 1998 David was appointed Head of Biotechnology at Covance and then in 2002 he moved to Q1 Biotech Ltd as Director of Operations – Biomanufacturing. Following the acquisition of Q1 Biotech by BioReliance (which was subsequently acquired by Invitrogen in 2003), David was appointed Director of Market Development and Global Manufacturing at Invitrogen.  In 2004 he was appointed Director of Operations at BioReliance Europe before joining Intercell in 2007.